BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30467187)

  • 1. A small change makes a big difference in Hodgkin lymphoma.
    Hutchings M
    Blood; 2018 Nov; 132(21):2214-2215. PubMed ID: 30467187
    [No Abstract]   [Full Text] [Related]  

  • 2. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
    Cheson BD
    Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of positron emission tomography in diagnosing subcutaneous panniculitis-like T-cell lymphoma.
    Bennani-Baiti B; Yadav S; Flynt L; Bennani-Baiti N
    J Clin Oncol; 2015 Apr; 33(10):1216-7. PubMed ID: 25691676
    [No Abstract]   [Full Text] [Related]  

  • 4. Update on Hodgkin lymphoma from a radiologist's perspective.
    Levine I; Kalisz K; Smith DA; Tirumani SH; Ramaiya NH; Alessandrino F
    Clin Imaging; 2020 Sep; 65():65-77. PubMed ID: 32361412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma.
    Rhodes MM; Delbeke D; Whitlock JA; Martin W; Kuttesch JF; Frangoul HA; Shankar S
    J Pediatr Hematol Oncol; 2006 May; 28(5):300-6. PubMed ID: 16772881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC
    J Clin Oncol; 2015 Apr; 33(10):1217. PubMed ID: 25691675
    [No Abstract]   [Full Text] [Related]  

  • 7. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
    McCarten KM; Nadel HR; Shulkin BL; Cho SY
    Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
    Adams HJ; Kwee TC
    N Engl J Med; 2016 Sep; 375(10):999. PubMed ID: 27602677
    [No Abstract]   [Full Text] [Related]  

  • 10. Imaging for Staging and Response Assessment in Lymphoma.
    Johnson SA; Kumar A; Matasar MJ; Schöder H; Rademaker J
    Radiology; 2015 Aug; 276(2):323-38. PubMed ID: 26203705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas.
    Kostakoglu L
    Clin Lymphoma Myeloma; 2008 Oct; 8(5):273-6. PubMed ID: 18854280
    [No Abstract]   [Full Text] [Related]  

  • 12. Prospective study of 18F-FDG PET in pediatric mediastinal lymphoma: a single center experience.
    Edeline V; Bonardel G; Brisse H; Foehrenbach H; Pacquement H; Maszelin P; Gaillard JF; Michon J; Neuenschwander S
    Leuk Lymphoma; 2007 Apr; 48(4):823-6. PubMed ID: 17454646
    [No Abstract]   [Full Text] [Related]  

  • 13. High-risk interim PET negative patients in Hodgkin's lymphoma.
    Meignan M
    Lancet Haematol; 2016 Oct; 3(10):e449-e450. PubMed ID: 27692302
    [No Abstract]   [Full Text] [Related]  

  • 14. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease.
    Paes FM; Kalkanis DG; Sideras PA; Serafini AN
    Radiographics; 2010 Jan; 30(1):269-91. PubMed ID: 20083598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance imaging in pediatric lymphoma.
    Voss SD; Cairo MS
    Pediatr Radiol; 2019 Oct; 49(11):1565-1573. PubMed ID: 31620855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained.
    Hindié E; Mesguich C; Bouabdallah K; Milpied N
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1254-1257. PubMed ID: 28466283
    [No Abstract]   [Full Text] [Related]  

  • 17. Staging and evaluation of the patient with lymphoma.
    Cheson BD
    Hematol Oncol Clin North Am; 2008 Oct; 22(5):825-37, vii-viii. PubMed ID: 18954739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
    Chiusolo P; Sica S; Leone G
    Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
    Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma.
    Cheng G; Servaes S; Zhuang H
    Leuk Lymphoma; 2013 Apr; 54(4):737-42. PubMed ID: 22957898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.